The results are reported of a randomized prospective clinical trial carried out to assess the value of specific active immunotherapy using irradiated autologous tumour cells in patients with glioblastoma multiforme treated by radical surgery and post-operative irradiation. The results in 62 patients show no statistically significant difference in survival between the group receiving adjuvant autologous tumour cells and those treated with surgery and radiotherapy alone. All 27 patients receiving tumour cells were dead at 30 months, whereas 7 of the 35 controls were alive at this time. The results were considered sufficiently discouraging to abandon the trial at this stage on the grounds that there was sufficient evidence in this study that the administration of irradiated autologous cells was of no benefit to patients with high grade astrocytomata.
About this article
Cite this article
Bloom, H., Peckham, M., Richardson, A. et al. Glioblastoma Multiforme: A Controlled Trial to Assess the Value of Specific Active Immunotherapy in Patients Treated by Radical Surgery and Radiotherapy. Br J Cancer 27, 253–267 (1973). https://doi.org/10.1038/bjc.1973.30
Reviews in the Neurosciences (2018)
Therapeutic Advances in Medical Oncology (2017)
Cellular and Molecular Life Sciences (2015)
Expert Review of Vaccines (2011)